4-[[4-(4-chloroanilino)phthalazin-1-yl]methyl]-N-methylpyridine-2-carboxamide;methanesulfonic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-[[4-(4-chloroanilino)phthalazin-1-yl]methyl]-N-methylpyridine-2-carboxamide;methanesulfonic acid
• 化学式: C24H26ClN5O7S2
• 分子量: 596.1
• InChiKey: QDDUGSRMQBJINW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.38
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  205
• 氢给体数：
  4
• 氢受体数：
  11

文献信息

• [EN] SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY<br/>[FR] PYRIDAZINES SUBSTITUEES ET PYRIDAZINES FUSIONNEES POSSEDANT UNE ACTIVITE D'NHIBITION DE L'ANGIOGENESE
  申请人：BAYER AG

  公开号：WO2001010859A1

  公开（公告）日：2001-02-15

  Substituted and fused pyridazines having angiogenesis inhibiting activity and generalized structural formula (I) wherein the ring containing A, B, D, E, and L is a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R?1 and R2¿ may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes using these materials are also disclosed.

  具有抑制血管生成活性的取代和融合吡啶并噻唑化合物，其具有广义结构式（I），其中包含A，B，D，E和L的环是含氮杂环；X和Y基团可以是各种定义的连接单元之一；R?1和R2¿可以是定义独立的取代基，或者一起可以是定义环的桥；环J可以是芳香族，吡啶基或环烷基团；G基团可以是各种定义的取代基。还公开了含有这些材料的制药组合物以及使用这些材料治疗具有异常血管生成或高渗透性过程的哺乳动物的方法。
• Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
  申请人：Adams E. Paul

  公开号：US20050019424A1

  公开（公告）日：2005-01-27

  The invention relates generally to the use of certain substituted fused or unfused pyridazine or pyridine derivatives which are KDR inhibitors in combination with other chemotherapeutic agents for use in treatment of diseases associated with abnormal angiogenesis and/or hyperpermeability and/or hyperproliferative diseases, such as cancer.

  本发明总体上涉及某些取代的融合或未融合哒嗪或吡啶衍生物的用途，这些衍生物是 KDR 抑制剂，与其他化疗药物联用，用于治疗与异常血管生成和/或高渗透性和/或高增殖性疾病（如癌症）相关的疾病。
• SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY
  申请人：Bayer Corporation

  公开号：EP1208096B1

  公开（公告）日：2004-04-28
• ANTI-ANGIOGENESIS COMBINATION THERAPIES COMPRISING PYRIDAZINE OR PYRIDINE DERIVATIVES
  申请人：Bayer Pharmaceuticals Corporation

  公开号：EP1467736A2

  公开（公告）日：2004-10-20
• Novel epoxy compound having alicyclic structure, polymer, resist composition and patterning process
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：US20030036603A1

  公开（公告）日：2003-02-20

  Epoxy compounds of formula (1) are provided wherein W is CH 2 , O or S, X and Y are —CR 1 R 2 — or —C(═O)—, k is 0 or 1, R 1 and R 2 are H or alkyl, or R 1 and R 2 , taken together, may form an aliphatic hydrocarbon ring with the carbon atom to which they are connected. A resist composition comprising a polymer having recurring units of the epoxy compound as a base resin is sensitive to high-energy radiation, has excellent sensitivity, resolution, etching resistance, and minimized swell and lends itself to micropatterning with electron beams or deep-UV. 1